Sudden unexpected death in epilepsy (SUDEP) has been recognised for centuries. The precise frequency of occurrence is not well defined. Education of medical professionals is needed, so that death certificates and coronial inquests may appropriately, correctly and consistently record SUDEP as the case of death. Correct identification will then allow further investigation of this misunderstood, and often ignored. epilepsy complication.
INTRODUCTION
Patients with epilepsy have a mortality rate which is significantly greater than the general population'. The excess is composed of an increased incidence of intracranial neoplasm, increased incidence of seizure related death, i.e. accidents, asphyxia/aspiration and status epilepticus, and an increased incidence of sudden unexpected death.
Sudden unexpected death in epilepsy (SUDEP) has been recognised for centuries, and pre-dates the widespread use of modem antiepileptic drugs (ABDs). It, as the name implies, is the occurrence of unexpected (and unexplained) ficulties the precise frequency is difficult to quantify3, but appears to be increasing". Some SUDEPs may be avoidable if causative factors can be correctly identified and avoided, mitigated or eliminated. Education of medical professionals who necessarily document these unfortunate deaths is urgently needed, so that death certificates and coronial inquests may appropriately, correctly and consistently record SUDEP as the cause of death. Consequently, when correct case ascertainment data are available further prospective studies of SUDEP mechanisms will become feasible.
Recently reported SUDEP series deal with rather small numbers of patients and, consequently, small errors in numerator data can lead to significant errors in incidence estimate calculations. However, perhaps surprisingly, all the independent series compute a SUDEP risk of 1:370 to 1:1110 patient treatment years3v5T6. Of much more concern is an apparent association of SUDEP with carbamazepine.
All currently available AEDs have been associated with SUDEP, and initial impressions have been that the relative proportion of patients suffering SUDEP is representative and proportionate to average AED usage for a particular time and region. However, our series suggests that this assumption is not necessarily correct, and shows a strong bias towards carbamazepine as an associated factor.
PATIENTS AND METHODS
A prospective record of epilepsy patient deaths was maintained by the Cardiff Epilepsy Unit between 1984 and 1992. For each case the register logged the cause of death, and also recorded associated factors: seizure types(s), AED therapy, demographic data and social circumstances of each deceased patient. The number of SUDEPs was extracted from the death register by subtracting deaths due to seizure-related events (i.e. accidents) and non-seizure-related deaths due to other medical conditions or events (e.g. tumours, cardiac disease, non-seizure-related accidents, suicide, etc.).
This method identified 14 episodes of SUDEP. Yearby-year analysis of the total number of patients registered with the Unit allowed calculation of total patientyears and equated to 7000 patient-treatment-years, and produced a calculated SUDEP rate of 1 SUDEP per 500 patients per year.
RESULTS
Analysis of the data collected produced results which parallelled the base population in many respects, and these are summarised in tables l-6. Age at death ranged from 20-69 years and most patients were aged 20-40 years, (mean: 35 years). Eleven of the 14 SUDEP patients were single, widowed or separated, and lived or slept alone.
Two strong statistically significant differences emerged:
(1) a strong association of SUDEP with carbamazepine usage;
(2) an association of SUDEP with living/sleeping alone.
DISCUSSION
The overall rate of SUDEP in this patient group of one death per 500 patient-years was similar to other reports, which range from l/l 110 to 1/37O3,6.7. This is the first series to suggest a specific bias towards carbamazepine (P c 0.01) as a risk factor. Previous retrospective analyses have tended to reflect average AED use for the respective time and location. The mechanism of the possible adverse carbamazepine effect is unclear, and requires further evaluation. It may relate to carbamazepine-induced lengthening of the ECG Q-T interval combined with a mild pro-arrhythmic effect of epileptic seizure discharges, with consequent transient cardiac instability leading to arrhythmic death (tachy-arrhythmias and episodes of sinus arrest have been documented)3.8-'6. This mechanism may also be relevant in cases of SUDEP occurring in patients taking oxcarbazepine.
Another potential mechanism that merits further investigation is the concept of excessive 'brainstem inhibition', due to seizure-induced release of GABA and other neuro-inhibitory peptides. This is a normal (physiological) endogenous seizure-terminating mechanism. However, excess brainstem inhibition could result in blunting or transient abolition of central hypoxic and hypercarbic respiratory drive, resulting in post-ictal respiratory arrest, subsequent exacerbation of hypoxia, further cardiac de-stabilisation and death due to hypoxia and secondary cardiac arrhythmia. This mechanism appears to have a degree of plausibility, as recent observational SUDEP data suggest that death might occur after, rather than during, a seizure, as a consequence of failed re-establishment of respiration in the post-ictal phase.
CONCLUSION
Current knowledge about SUDEP remains poor. Further education is needed so that case ascertainment can be correctly documented. Research into the precise mechanisms involved should lead to definitive prevention strategies. Further study to evaluate the role of carbamazepine as a causative factor in SUDEP is also needed, but in the interim caution with carbamazepine use seems prudent.
